Directorio

Es posible que algunos contenidos no estén disponibles en español.
438 clinical trials found.
Digestive System

Compensation: No
Non-Oncology
Older Adults/Aging

We are doing this study to help us identify the underlying causes of brain disorders such as delirium and/or dementia.

Compensation: Yes
Ages: 60-110
Non-Oncology
Duke University Hospital, Duke Regional Hospital, Duke Raleigh Hospital
Gastrointestinal Cancer

We are doing this study to find out if an experimental drug called Lutetium Lu 177 dotatate (the study drug) has the potential to shrink or stabilize bronchial neuroendocrine tumors. We will compare how the study drug works to everolimus, which is the usual drug used for this diagnosis.

Compensation: No
Ages: 18-110
Oncology
Duke University Hospital
Genitourinary Cancer

We are doing this study to find out if a medical technology called the Signatera blood test can help doctors and patients determine the best course of treatment for bladder cancer after the patient has a radical cystectomy (removal of the bladder and surrounding lymph nodes). The Signatera test is used to detect cancer DNA in the blood before cancer can be seen using imaging (like MRI or CT scans).

Compensation: No
Ages: 18-110
Oncology
Duke University Hospital, Duke Raleigh Hospital, Other
Genitourinary Cancer

The purpose of this study is to determine whether an experimental blood test (Signatera®) can help us make better decisions about who should get immunotherapy after surgery to remove the bladder for bladder cancer and which immunotherapy treatment will be the best choice.

Compensation: No
Ages: 18-110
Oncology
Duke University Hospital, Duke Raleigh Hospital
Eyes and Vision

We are doing this study to find out if an investigational gene therapy drug called ABBV-RGX-314 (the study drug) is a safe and effective option for people with diabetic retinopathy. The study drug is delivered directly into the suprachoroidal space of the eye using a technology called Microinjector®, which is an experimental needle device.

Compensation: Yes
Ages: 25-89
Non-Oncology
Duke University Hospital
Transplant Medicine

We are doing this study to find out if an experimental drug called ALXN2030 (the study drug) is a safe and effective option for people diagnosed with antibody-mediated rejection (AMR) of a transplanted kidney.

Compensation: Yes
Ages: 18-75
Non-Oncology
Duke University Hospital